Global Hepatic Encephalopathy Market, by Drug Class (Laxatives, L-aspartate, Antibiotics, L-aspartate and others), by Route of Administration (Oral, Rectal and Intravenous), by Distribution Channel (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies,), and by Region (Latin America, Europe, Asia Pacific, North America, Africa, and Middle East). In 2020, the market is expected to be worth US$ […]
Hepatic Encephalopathy Market Expected to Grow by US$ 355.4 Mn by 2027
Global Hepatic Encephalopathy Market, by Drug Class (Laxatives, L-aspartate, Antibiotics, L-aspartate and others), by Route of Administration (Oral, Rectal and Intravenous), by Distribution Channel (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies,), and by Region (Latin America, Europe, Asia Pacific, North America, Africa, and Middle East). In 2020, the market is expected to be worth US$ 355.4 million, with a CAGR of 5.3 percent during the forecast period (2020-2027).
The increasing prevalence of various risk factors such as hepatitis C and hepatic cirrhosis among the population is likely to boost the worldwide hepatic encephalopathy market growth. According to the CMAJ Open journal: 2018, the prevalence of liver cirrhosis in the Canadian population is predicted to rise due to increased incidence of hepatitis C and non-alcoholic fatty liver disease. In Canada, over 30% of the population suffers from liver disease.
Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/2596
Market participants are engaged in inorganic activities such as acquisitions, which are projected to broaden product portfolios and enhance company positions in the global market. Ferring Pharmaceuticals Inc., for example, purchased Rebiotix Inc., a clinical-stage biotechnology company, in 2018. This merger brought together two healthcare firms that are dedicated to researching and understanding the human micro biome in order to develop new treatments for patients.
Impact of Coronavirus (COVID – 19) Pandemic:
The global hepatic encephalopathy market is projected to be slowed by the COVID-19 pandemic. The majority of individuals suffering from significant liver damage require hepatic encephalopathy treatment, according to the National Center for Biotechnology Information (NCBI), and treatment may be delayed owing to the pandemic. Although, due to the lack of antibiotics, laxatives, and other medications, as well as erratic supply and transportation of medicine during the COVID-19 pandemic, the treatment of severe liver damage patients is postponed or even cancelled.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/2596
Furthermore, the COVID-19 pandemic has disrupted the global drug supply, according to the US Food and Drug Administration (FDA), due to government-mandated or recommended temporary shutdowns, safety initiatives to ensure employee health and well-being, insufficient labor force, and restrictions on import and export activities, as well as travel. Antibiotic production has long been a particularly affected.
Clinical studies for the development of novel medications for hepatic encephalopathy are projected to fuel growth of the worldwide hepatic encephalopathy market throughout the forecast period, according to key competitors. Mallinckrodt Pharmaceuticals, for example, conducted clinical trials in 2019 for MNK-6105 (ornithine phenylacetate) intravenous and MNK-6106 (ornithine phenylacetate) oral drugs to prevent chronic hepatic encephalopathy recurrence. Currently, the trial is in its third phase.
Key Takeaways:
Due to expansion in promising markets, particularly in Europe, the worldwide hepatic encephalopathy market is predicted to increase at a CAGR of 5.3 percent over the projected period (2020-2027). North America accounted for the major share of the market.
The worldwide hepatic encephalopathy market is predicted to rise due to the rising availability of lactulose for the treatment of hepatic encephalopathy. For example, in April 2017, Cumberland Pharmaceuticals, a specialty pharmaceutical company based in the United States, and Poly Pharmaceuticals Inc., a privately held specialty pharmaceutical company based in the United States, signed an agreement to promote the Kristalose (lactulose solution for the treatment of hepatic encephalopathy) developed by Poly Pharmaceuticals Inc. in the United States. Kristalose’s present sales will be increased in the United States as a result of this multi-year co-promotion collaboration.
Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2596
Major Players Are: ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V., Abbott Laboratories, and QR Science and Technology Development Co. Ltd.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Hepatic Encephalopathy Market in Pharmaceutical industry | estimates US$ 355.4 Mn growth during 2021-2027 appeared first on Gatorledger.
